123 results about "Corneal endothelium" patented technology

An apparatus and a method for operating an endothelium reflection microscope. The apparatus comprises an optical head including: an illuminating system, an eye-front observation optical system along a central channel in which an alignment-use light spot is received and imaged by a camera comprising a digital optical sensor, and an enlarged-imaging optical system for enlarged observation or photographing of the subject part of the digital camera. The apparatus further comprises a drive for moving the optical head and a CPU controller for automatically controlling the drive, the illuminating system and the eyefront optical system. The method comprises an endothelium image acquisition procedure in which the grey level inside a check area of the camera sensor is constantly checked during the advancement along an advancement direction (Z-); when the grey level reaches a predetermined threshold value, a delay time (Δt) is triggered; and when the delay time (Δt) lapses, the acquisition of one or more images of the endothelium by the digital camera is enabled.

The invention provides a corneal endothelial composition comprising a transparent hydrogel scaffold and a single layer of cultured corneal endothelial cells on the surface of the scaffold. The hydrogel scaffold I comprised of at least one biopolymer, preferably gelatin. Also provided are methods of making a corneal endothelial scaffold

The present invention discloses a biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet comprising a monolayer of interconnected HCECs with substantially uniform orientation, wherein the bioengineered cell sheet is attached to a surface of the carrier with apical surfaces of the HCECs facing said carrier.

An ocular stent for insertion in an anterior chamber of an eye is provided. The stent facilitates the restoration of the structure of an irideocorneal angle of the anterior chamber for treating structural changes from ocular aging. The stent includes an annular body sized to fit in the irideocorneal angle of the eye. The body includes: an anterior portion configured to contact a surface of a transition zone between a trabecular meshwork and a corneal endothelium of the eye; a posterior portion configured to contact a peripheral iris of the eye; and a central portion connecting the anterior portion and the posterior portion of the body. A method for stabilizing the iredeocorneal angle of the anterior chamber using a stent is also disclosed herein.

A cornea imaging apparatus including: a collimation axis holding mechanism; an imaging mechanism; a Z-direction actuating means; an X-direction actuating means and a Y-direction actuating means; an inclination angle changing means that changes an inclination angle of an imaging center axis of the imaging mechanism against a collimation axis of an eye under examination; an endothelial configuration computing means that determines a corneal endothelial configuration; and a normal vector computing means that determines a normal vector direction at a given imaging position of the corneal endothelial configuration, wherein at the imaging position, the inclination angle and positions in the Z and X directions are set adjusted so as to align the imaging center axis of the imaging mechanism with the normal vector direction determined by the normal vector computing means.

Described herein are methods and compositions for stimulating proliferation of cells that express adherent junctions and cease proliferation, for example, human corneal endothelial cells, by downregulation of certain cell-cell junctions. In one embodiment, downregulation is achieved using RNA interference, and contacting the cells with mitogenic growth factors and an agent that elevates intracytoplasmic cAMP. Furthermore, described herein are methods of isolating human corneal endothelial cells from keratocytes, and methods of preserving and maintaining viability of human corneal endothelial cell aggregates. Also described are surgical grafts comprising human corneal endothelial cells that have been isolated, optionally stored, and transiently contacted with an agent that downregulates expression of p 120, and a biocompatible support. The methods and compositions described herein can be used in novel therapies to help expand human corneal endothelial cells during in vitro tissue engineering and for in vivo treatment of corneal endothelial dysfunction.

A method for expanding human corneal endothelial cells includes: (a) providing an amniotic membrane with or without amniotic cells, wherein the amniotic membrane has an extracellular matrix; (b) placing onto the amniotic membrane, a sheet of endothelial layer, or a cell suspension including human corneal endothelial stem cells; and (c) culturing the corneal endothelial cells on the amniotic membrane for a duration sufficient for the corneal endothelial stem cells to expand to an appropriate area. The invention also relates to a method for creating a surgical graft for a recipient site of a patient using the method for expanding human corneal endothelial cells, and the surgical graft prepared therefrom.

The invention discloses a femtosecond laser cataract surgery treatment device which comprises an optical coherence tomography scanning imaging system, a data processing system, a laser light source system, a laser energy detection system, a laser scanning system and a press mirror. The laser light source system is provided with a femtosecond laser. The laser light source system and the laser energy detection system, the laser energy detection system and the laser scanning system, the laser scanning system and the optical coherence tomography scanning imaging system are respectively connected through a light beam transmission system. The femtosecond laser cataract surgery treatment device has the advantages that the device is precise, efficient and safe, and astigmatism and endophthalmitis after operation are avoided; envelope tearing and suspensory ligament injury are reduced, surrounding tissue injuries are small; complications produced during crystal nucleus emulsification and artificial lens implantation are decreased as far as possible; the operating difficulty is reduced; the required energy for ultrasonic emulsification is greatly decreased, and the corneal endothelium is effectively protected.

The invention relates to an instrument for preparing an corneal endothelial graft, the tool being a trephine blade (1) having a cross section in the form of an arc of a circle of between 270° and 355°. The invention also relates to a method of preparing a graft using such an instrument.

The construction of human corneal endothelium cell line with corneal endothelium as material includes the steps of: the first adherent culture of human corneal endothelium cell inside DMEM/F12 culture liquid with ox embryo serum in 20 wt%, chondroitin sulfate oxidizing and degrading matter, epidermal cell growth factor, basic fibroblast growth factor and ox eye auxin to obtain pure corneal endothelium cell; and the subsequent secondary culture in trypsinization process. The technological process is scientific and reasonable, and up to now, passage cell of 106-th generation has been obtained. The human corneal endothelium cell line of the present invention has no any virus or cancer genetic transfection, has no any tumorigenicity, and is expected to be used in direct artificial cornea production and clinical application.

A device transfers donor endothelial cells to the cornea of a recipient without injuring the cells or the cornea during the transfer process. The device transfers living endothelial cells from a donor to a recipient with minimal or no trauma. The device includes a handle, an irrigation tube lengthwise within the handle, a button upon the handle concentric with the irrigation tube, a tapered nose opposite the button, a forward tube extending outwardly from the nose, and a platform joined to the irrigation tube. The forward tube has an elliptical cross section and two beveled features. The platform has two wings that curl gently around donor tissue upon retracting the platform into the forward tube. The handle has a groove for a stem of a knob that surgeon presses and pulls to move the platform.

The invention provides a cornea metaphase preservation solution, and preparing and using methods thereof. The cornea metaphase preservation solution is a cell culture minimum essential medium (MDM) with chondroitin sulfate, low molecular dextran, L-glutamine, dexamethasone, tobramycin, 2-hydroxyethyl and Y-27632 added. The preservation solution not only can keep activity and normal morphology of cornea endothelial cells, but also can enhance viability of corneal limbus epithelial cells and improve clone ability of corneal limbus stem cells. And especially, a medium to long term preservation effect is obvious, phenomena of deformation, conjugation and the like of endothelial cells of a control group cornea do not appear in long term preservation, endothelial morphology of the control group cornea is consistent with endothelial morphology of a cornea preserved for 4 days, and the endothelial cells of the control group cornea are still regular and few in cell conjugation phenomena. The preservation solution can effectively prevent cell apoptosis phenomena during the process of preserving isolated cornea materials, increases activity and clone forming ability of the corneal limbus stem cells, and enables the cornea to maintain a transparent feature in a long preservation time.

The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

The invention relates to a corneal posterior lamella. The corneal posterior lamella is prepared by the following method: (a) separating and culturing cat corneal endothelial precursor cells for obtaining corneal endothelial precursor cells; (b) preparing a porcine corneal acellular matrix and obtaining the acellular matrix; and (c) constructing the corneal posterior lamella. The invention further provides a use of using the corneal posterior lamella as a donor for corneal transplantation. The structure of the tissue engineering corneal posterior lamella constructed by the corneal endothelial precursor cells is similar to the structure of the normal corneal posterior lamella. The construction of the corneal posterior lamella by taking the corneal endothelial precursor cells as seeds can provide sufficient cell sources, overcome the difficult problem of low proliferation capacity of the corneal endothelial cells and simultaneously solve the problems of cell transformation and safety.

The invention relates to a method for preparing a carrier bracket of tissue engineering artificial corneal endothelium by using a fresh amniotic membrane. The method comprises the following steps: soaking and disinfecting the fresh amniotic membrane by tobramycin sulfate injection according to the mass ratio of 1:1000; after reverse digestion using trypsin-EDTA digestive juice, lightly scraping the epithelial surface of the amniotic membrane by a cell scraper to completely remove residual epithelial cells to obtain the denuded amniotic membrane which is tiled in culture plate holes for fixingand dry-posting; coating by special coating liquid for the denuded amniotic membrane; and sucking and then drying the coating liquid to obtain the carrier bracket of the tissue engineering artificialcorneal endothelium. The method has scientific and reasonable process, the prepared carrier bracket can be mass produced to meet the heavy demand of scale reconstruction of the tissue engineering artificial corneal endothelium and create conditions for sight rehabilitation of corneal endothelium blindness through clinical corneal transplantation, and the preparation method of the carrier bracket has low cost in in-vitro reconstruction and clinical treatment of the tissue engineering artificial corneal endothelium.

The invention provides an eyelid retractor which can fix eyeballs, and comprises a C type body (1), two arms (2), and components (3) which are adhered on the ends of an upper and a lower two arms and can be fixed on the skin, wherein the intra-annular diameter of the C type body (1) is the same as the diameter of an adult cornea, a base face of the C type body (1) is arranged at a radian at which the C type body (1) is in the anastomosis with a conjunctiva sac, and the C type body (1) of the eyelid retractor can be blocked at the edge of a corneosclera, thereby achieving the purpose of fixing eyeballs. The eyelid retractor can be used in the ophthalmic surgeries and/or ophthalmic examinations in which patients are asked to widely open eyes and keep fixed eyesight, such as the forward centesis, the anterior segment laser surgery, the optical coherence tomography technique (OTC) examination, the heidelberg retina tomograph (HRT) examination, the optic nerve fiber thickness analyzing (GDx) or the corneal endothelium counting.

The invention discloses an in-vitro separation and purification method for tree-shrew corneal endothelial cells. The in-vitro separation and purification method includes the steps that tree-shrew corneal endothelial cells are separated, purified and subjected to passage cultivation through CECs, and corneal endothelial cells are obtained. The separated corneal endothelial cells have high cell activities, purification of the corneal endothelial cells can be achieved in the passed P3 generation is passed, the purified cells have typical endothelial cell morphology, and are identified through NSE immunofluorescence, and the dyeing rate is high. The purification efficiency of the method is greatly improved, the cost is low, using is convenient, and the large quantity of tree-shrew corneal endothelial cells can be obtained. In-vitro cultivation of the tree-shrew corneal endothelial cells is achieved, and the void that a specific corneal-endothelial-primary-cell in-vitro cultivation technology for a tree-shrew species does not exist ate present is filled; the material taking and purification methods of primary cells are easy to operate, the cost is low, and in-vitro cultivation tree-shrew corneal endothelial cells can be kept the good cell states in the long-term passage cultivation process.

The invention discloses a method of constructing a corneal endothelium of tissue engineering by utilizing a live amnion upper skin graft. The method comprises the steps: acquiring the live amnion upper skin graft; and constructing the corneal endothelium of the tissue engineering by virtue of the live amnion upper skin graft. With the adoption of the method, as shapes, the arrangement, tissue structures, biological functions and the like of cells of the adopted live amnion upper skin graft are similar to the corneal endothelium, the live amnion upper skin graft can be adopted to replace the corneal endothelium with dysfunction, the normal functions of cornea is maintained, and the cornea transparency is improved.

The invention provides an inducing culture medium for inducing to produce corneal endothelial cells. The inducing culture medium is characterized by taking a DMEM (Dulbecco Modified Eagle Medium)/F12 culture medium as a basic culture medium, and is prepared from the following components: beta-mercaptoethanol of which the molar concentration is 0.05 to 0.15 mmol/L, glutamine of which the molar concentration is 0.05 to 0.15 mmol/L, bFGF (Basic Fibroblast Growth Factors) of which the mass concentration is 4 to 8 ng/ml, NEAA (Non Essential Amino Acid) of which the molar concentration is 0.05 to 0.15 mmol/L, KSR (Knockout Serum Replacement) of which the volume concentration is 18 to 25 percent and RA of which the molar concentration is 0.5 to 2 mu mol/L. The invention also provides a method for inducing an embryonic stem cell to be differentiated into the corneal endothelial cells, wherein the corneal endothelial cells which are obtained through inducing are obvious in morphology rule feathers. The method does not involve a feeder layer, so that other animal origin pollution is avoided, and the biological safety is high; the corneal endothelial cells are used as corneal endothelium seed cells in tissue engineering, so that a qualified material source is provided for clinical corneal endothelium transplantation.

The invention relates to an intraocular lens loaded with drug slow-releasing thin layers on loop surfaces. The purpose of the invention is that the provided intraocular lens can effectively prevent and control microbial infection and antagonism inflammatory response after a cataract surgery, reduce the occurrence rate of intraocular inflammation after the cataract surgery and prevent and inhibit after-cataract, therefore improving the postoperative visual quality; at the same time, the stability on aspects such as optics and mechanics of the intraocular lens is not influenced; the intraocular lens does not have a toxic or side effect on intraocular tissues such as the corneal endothelium of a body, epithelial cells of a ciliary body, irises, choroids, retina and the like; the provided production method is simple, mature and practical, the cost of raw materials is low, and industrialized mass production can be realized. According to the technical scheme, the intraocular lens loaded with the drug slow-releasing thin layers on the loop surfaces comprises an optical part and at least two loops symmetrically arranged on the side edge of the optical part. The intraocular lens is characterized in that the surfaces of the loops are coated with the drug slow-releasing thin layers, and the thin layers contain antibacterial or/and anti-inflammatory or/and after-cataract cataract resisting drugs.